Efficacy of the oral use of the drug N-acetylcysteine in the treatment of facial melasma in wome

Not Applicable

• Conditions: Melasma

• Registration Number: RBR-73zrnjh
• Lead Sponsor: Faculdade de Medicina de Botucatu (FMB - Unesp)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-02-21
• Study Completion: 2022-06-30
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Women with facial melasma 18 to 60 years old, Fitzpatrick's phototypes II to V

Exclusion Criteria

Patients with other concomitant facial skin diseases, skin diseases with photosensitivity, melasma with mMASI less than 5, history of hypersensitivity to the active substance oral melatonin or to any other component of the formulation described, pregnant or lactating women.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assessment of the severity of melasma assessed through the mMASI Score (modified Melasma Area and Severity Index); evaluation at T0 and T8 (60th day of treatment); a percentage reduction of at least 20% is expected in T8 compared to T0

Secondary Outcome Measures

Name	Time	Method
Improved quality of life in patients with internationally validated melasma; evaluation at T0 and T8 (60th day of treatment) using the MELASQoL scale;